Neal Bhatia, MD

Drs Raj Chovatiya and Neal Bhatia highlight the biological targets of current and emerging treatments for the management of atopic dermatitis and discuss the importance of safety and long-term data.

Raj Chovatiya, MD, PhD, and Neal Bhatia, MD, share their thoughts on the clinical implications of the rapid expansion of the atopic dermatitis treatment armamentarium.

Drs Angela Lamb, Omar Noor, and Neal Bhatia share what they consider to be the biggest gaps in care for patients with SOC: patient/provider education, building trust, and appropriate diagnosis of AD.

Three dermatologists discuss the case of an 18-year-old patient with AD who is exploring nonsteroidal options to manage his disease.

Drs Noor and Bhatia have a conversation about cost and financial assistance from pharmaceutical companies.

Drs Bhatia and Lamb discuss the case of a 12-year-old child with asthma and how they would manage his disease.

Experts discuss the case of a 4-year-old girl with lighter skin and treatment options for a young child.

Three experts emphasize the importance of setting expectations for AD treatment with patients.

Drs Noor and Lamb discuss mechanisms of action of biologics and JAK inhibitors and the importance of patient communication while selecting AD treatments.

Drs Lamb, Noor, and Bhatia discuss their approach to selecting treatment in light of recent AD approvals.

Drs Noor and Lamb highlight the importance of frank discussion of adverse effects of atopic dermatitis treatments with patients.

Drs Bhatia, Lamb and Noor talk about the importance of building trust with patients and highlight topics to discuss with patients and parents.

Dermatology experts discuss strategies to increase awareness of advances in AD in patients with SOC.

Drs. Neal Bhatia and Angela Lamb provide an overview of atopic dermatitis and its prevalence in patients with skin of color (SOC).

Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.

Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.

A review of topical JAK inhibitor ruxolitinib.

James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.